Skip to main content
. 2023 Apr 17;5(1):vdad041. doi: 10.1093/noajnl/vdad041

Figure 1.

Figure 1.

Figure 1.

(A) Duration of study treatment with reasons for treatment discontinuation and (B) best percentage change from baseline in meningiomas and schwannomas (n = 59).